What is Aptevo Therapeutics Inc's earnings per share (EPS)?

Aptevo Therapeutics Inc (APVO) reported diluted earnings per share of $-87.27 for fiscal year 2025. This represents a 99.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Aptevo Therapeutics Inc Financials

APVO

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Aptevo Therapeutics Inc (APVO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APVO FY2025 2026-05-13

Aptevo’s visible operating mechanic is external-capital-funded cash burn, with new financing restoring liquidity while the research platform still consumes cash.

Most recently, net loss and operating cash burn matched unusually closely, at -$26.0M and -$25.6M, after showing essentially the same relationship the year before. That alignment says the deficit is cash-real rather than mainly accounting noise; losses are not being cushioned by working-capital inflows or other noncash items, so runway depends heavily on continued access to financing.

The balance-sheet recovery was financing-driven: cash ended at $21.6M after $38.5M of financing inflow, not because the business started funding itself. That recapitalization also lifted the current ratio to 3.8x and reduced liabilities relative to equity, which makes the company look less constrained in the near term even though the underlying burn rate remains intact.

Spending is concentrated in R&D and corporate overhead, which ran at $14.5M and $11.8M most recently. With no reported revenue in the latest annual rows, operating results are being shaped far more by how aggressively management funds research and administration than by sales volume or gross-margin mix.

Financial Health Signals

Financial Profile 28/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Aptevo Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Aptevo Therapeutics Inc carries a low D/E ratio of 0.56, meaning only $0.56 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.81, Aptevo Therapeutics Inc holds $3.81 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 75/100.

Returns

Aptevo Therapeutics Inc generates a -149.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -507.5% the prior year.

Piotroski F-Score Neutral

4/9

Aptevo Therapeutics Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.99x

For every $1 of reported earnings, Aptevo Therapeutics Inc generates $0.99 in operating cash flow (-$25.6M OCF vs -$26.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$26.1M

YoY-7.5%

Aptevo Therapeutics Inc's EBITDA was -$26.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.5% from the prior year.

Net Income

-$26.0M

YoY-7.6%

Aptevo Therapeutics Inc reported -$26.0M in net income in fiscal year 2025. This represents a decrease of 7.6% from the prior year.

EPS (Diluted)

$-87.27

YoY+99.7%

Aptevo Therapeutics Inc earned $-87.27 per diluted share (EPS) in fiscal year 2025. This represents an increase of 99.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$21.6M

YoY+148.1%

5Y CAGR-11.6%

10Y CAGR+16.6%

Aptevo Therapeutics Inc held $21.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

997,830

YoY-31.6%

Aptevo Therapeutics Inc had 997,830 shares outstanding in fiscal year 2025. This represents a decrease of 31.6% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-149.4%

YoY+358.1pp

5Y CAGR-42.4pp

10Y CAGR-82.5pp

Aptevo Therapeutics Inc's ROE was -149.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 358.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$14.5M

YoY+1.1%

5Y CAGR-4.0%

10Y CAGR-8.3%

Aptevo Therapeutics Inc invested $14.5M in research and development in fiscal year 2025. This represents an increase of 1.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

APVO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$3.1M-74.7%	$12.3M+185.3%	$4.3M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$14.5M+1.1%	$14.4M-16.0%	$17.1M-4.3%	$17.9M-5.9%	$19.0M+6.4%	$17.9M
SG&A Expenses	$11.8M+15.1%	$10.2M-13.1%	$11.8M-15.2%	$13.9M-5.6%	$14.7M+5.4%	$14.0M
Operating Income	-$26.3M-7.0%	-$24.6M+14.8%	-$28.9M-0.8%	-$28.6M-33.8%	-$21.4M+22.2%	-$27.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	N/A	N/A	N/A	N/A
Net Income	-$26.0M-7.6%	-$24.1M-38.6%	-$17.4M-316.9%	$8.0M+128.2%	-$28.5M-60.3%	-$17.8M
EPS (Diluted)	$-87.27+99.7%	$-31460.23	$-2316.83	$1.57+125.9%	$-6.07	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.9M	N/A	$4.0M+21.5%	$3.3M-8.4%	$3.6M	N/A	$3.1M-14.8%	$3.6M
SG&A Expenses	$2.9M	N/A	$3.6M+23.1%	$2.9M+1.8%	$2.8M	N/A	$2.1M-11.4%	$2.4M
Operating Income	-$6.8M	N/A	-$7.6M-22.2%	-$6.2M+3.9%	-$6.5M	N/A	-$5.2M+13.5%	-$6.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.7M	N/A	-$7.5M-21.7%	-$6.2M+3.2%	-$6.4M	N/A	-$5.1M+13.3%	-$5.9M
EPS (Diluted)	$-6.41	N/A	$-2.23	$-8.40+99.5%	$-1581.81	N/A	$-357.86+71.1%	$-1236.96

APVO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$27.2M+74.4%	$15.6M-37.2%	$24.8M-27.4%	$34.2M-39.6%	$56.6M+5.7%	$53.5M
Current Assets	$23.1M+116.5%	$10.7M-44.1%	$19.1M-30.5%	$27.4M-47.8%	$52.6M+11.2%	$47.3M
Cash & Equivalents	$21.6M+148.1%	$8.7M-48.5%	$16.9M-25.3%	$22.6M-49.7%	$45.0M+12.7%	$40.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$9.8M-9.4%	$10.8M-14.1%	$12.6M-22.3%	$16.2M-70.7%	$55.4M+49.9%	$37.0M
Current Liabilities	$6.0M-2.5%	$6.2M-14.1%	$7.2M-17.0%	$8.7M-75.0%	$34.8M+139.1%	$14.5M
Long-Term Debt	N/A	N/A	$0-100.0%	$1.5M-60.7%	$3.7M-86.9%	$28.2M
Total Equity	$17.4M+265.5%	$4.8M-61.1%	$12.2M-32.0%	$18.0M+1378.1%	$1.2M-92.7%	$16.6M
Retained Earnings	-$275.1M-11.1%	-$247.6M-10.8%	-$223.4M-8.5%	-$206.0M+3.7%	-$214.1M-15.3%	-$185.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$19.9M-26.8%	$27.2M+0.7%	$27.0M+72.8%	$15.6M+87.3%	$8.3M-46.5%	$15.6M+2.9%	$15.1M+1.5%	$14.9M
Current Assets	$16.0M-30.7%	$23.1M+1.9%	$22.6M+104.4%	$11.1M+207.2%	$3.6M-66.2%	$10.7M+6.5%	$10.0M+4.5%	$9.6M
Cash & Equivalents	$14.5M-32.8%	$21.6M+2.6%	$21.1M+123.8%	$9.4M+339.9%	$2.1M-75.5%	$8.7M+12.4%	$7.8M-3.9%	$8.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.3M-15.5%	$9.8M+2.2%	$9.6M+5.5%	$9.1M-7.3%	$9.8M-9.4%	$10.8M+1.0%	$10.7M+2.6%	$10.5M
Current Liabilities	$4.8M-21.3%	$6.0M+7.8%	$5.6M+14.8%	$4.9M-9.3%	$5.4M-13.1%	$6.2M+5.5%	$5.9M+8.5%	$5.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$11.6M-33.2%	$17.4M-0.1%	$17.4M+166.6%	$6.5M+542.9%	-$1.5M-131.0%	$4.8M+7.6%	$4.4M-1.0%	$4.5M
Retained Earnings	-$281.9M-2.5%	-$275.1M-2.2%	-$269.2M-3.5%	-$260.2M-2.4%	-$254.0M-2.6%	-$247.6M-2.6%	-$241.3M-2.2%	-$236.2M

APVO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$25.6M-7.6%	-$23.8M-102.8%	-$11.7M+44.2%	-$21.0M+3.0%	-$21.7M+26.1%	-$29.3M
Capital Expenditures	N/A	N/A	N/A	$29K-95.9%	$713K+710.2%	$88K
Free Cash Flow	N/A	N/A	N/A	-$21.1M+6.0%	-$22.4M+23.9%	-$29.4M
Investing Cash Flow	$0	$0	$0+100.0%	-$29K+95.9%	-$713K-102.5%	$28.0M
Financing Cash Flow	$38.5M+146.9%	$15.6M+160.0%	$6.0M+329.3%	-$2.6M-110.0%	$26.2M+9.6%	$23.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$8.0M-52.1%	-$5.2M+21.7%	-$6.7M+5.7%	-$7.1M-7.9%	-$6.6M-14.2%	-$5.8M-10.3%	-$5.2M+15.1%	-$6.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	N/A	N/A	N/A	$0	N/A	N/A	N/A
Financing Cash Flow	$871K-85.0%	$5.8M-68.4%	$18.3M+27.7%	$14.4M	$0-100.0%	$6.7M+36.9%	$4.9M+23.7%	$4.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

APVO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-919.8%-745.6pp	-174.1%+464.0pp	-638.1%
Net Margin	N/A	N/A	N/A	257.8%+489.3pp	-231.5%+180.4pp	-411.9%
Return on Equity	-149.4%+358.1pp	-507.5%-365.0pp	-142.5%-187.1pp	44.7%+2384.9pp	-2340.2%-2233.2pp	-107.0%
Return on Assets	-95.5%+59.3pp	-154.8%-84.7pp	-70.1%-93.5pp	23.5%+73.7pp	-50.3%-17.1pp	-33.1%
Current Ratio	3.81+2.1	1.72-0.9	2.64-0.5	3.15+1.6	1.51-1.7	3.25
Debt-to-Equity	0.56-1.7	2.28+2.3	0.00-0.1	0.08-3.0	3.05+1.3	1.70
FCF Margin	N/A	N/A	N/A	-676.0%-493.8pp	-182.2%+500.3pp	-682.4%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-57.7%	N/A	-43.4%+51.7pp	-95.1%	N/A	N/A	-115.4%+16.4pp	-131.8%
Return on Assets	-33.7%	N/A	-28.0%+11.8pp	-39.7%+37.1pp	-76.8%	N/A	-33.7%+5.8pp	-39.4%
Current Ratio	3.36-0.5	3.81-0.2	4.03+1.8	2.27+1.6	0.67-1.0	1.72+0.0	1.70-0.1	1.77
Debt-to-Equity	0.71+0.1	0.56+0.0	0.55-0.8	1.39+8.1	-6.66-8.9	2.28-0.1	2.43+0.1	2.34
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Xenetic Biosciences Inc XBIO

$6.7M

GRI Bio GRI

$3.9M

Onconetix ONCO

$1.4M

Oragenics OGEN

$2.7M

Quoin Pharmaceuticals Ltd QNRX

$9.7M

Frequently Asked Questions

Is Aptevo Therapeutics Inc profitable?

No, Aptevo Therapeutics Inc (APVO) reported a net income of -$26.0M in fiscal year 2025.

What is Aptevo Therapeutics Inc's EBITDA?

Aptevo Therapeutics Inc (APVO) had EBITDA of -$26.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Aptevo Therapeutics Inc's return on equity (ROE)?

Aptevo Therapeutics Inc (APVO) has a return on equity of -149.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Aptevo Therapeutics Inc's operating cash flow?

Aptevo Therapeutics Inc (APVO) generated -$25.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Aptevo Therapeutics Inc's total assets?

Aptevo Therapeutics Inc (APVO) had $27.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Aptevo Therapeutics Inc spend on research and development?

Aptevo Therapeutics Inc (APVO) invested $14.5M in research and development during fiscal year 2025.

How many shares does Aptevo Therapeutics Inc have outstanding?

Aptevo Therapeutics Inc (APVO) had 997,830 shares outstanding as of fiscal year 2025.

What is Aptevo Therapeutics Inc's current ratio?

Aptevo Therapeutics Inc (APVO) had a current ratio of 3.81 as of fiscal year 2025, which is generally considered healthy.

What is Aptevo Therapeutics Inc's debt-to-equity ratio?

Aptevo Therapeutics Inc (APVO) had a debt-to-equity ratio of 0.56 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Aptevo Therapeutics Inc's return on assets (ROA)?

Aptevo Therapeutics Inc (APVO) had a return on assets of -95.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Aptevo Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Aptevo Therapeutics Inc (APVO) had $21.6M in cash against an annual operating cash burn of $25.6M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Aptevo Therapeutics Inc's Piotroski F-Score?

Aptevo Therapeutics Inc (APVO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Aptevo Therapeutics Inc's earnings high quality?

Aptevo Therapeutics Inc (APVO) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Aptevo Therapeutics Inc?

Aptevo Therapeutics Inc (APVO) scores 28 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.